With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief

Atsushi Kamide, Chairman, Drug Pricing Committee, FPMAJ Japan positions its new cost-effectiveness assessment (CEA) scheme merely as a tool to complement the current drug pricing system, but Atsushi Kamide, who heads up the Federation of Pharmaceutical Manufacturers’ Associations of Japan’s...read more